Mersana Therapeutics Inc

NASDAQ:MRSN

5.02

+0.11 (+2.24%)

Products

Mersana Therapeutics Announces FDA Grant Of Orphan Drug Designation To XMT-2056

Published: 05/19/2022 11:08 GMT

MRSN

Mersana Therapeutics Inc (MRSN) - Mersana Therapeutics Announces FDA Grant of Orphan Drug Designation to Xmt-2056 for the Treatment of Gastric Cancer.